Search results

A new continuous record of temperature dating back 12,000 years provides an import resource in understanding current and future climate changes,

Grant supports development of handheld technology to verify origin of seafood.

Neutron Capture Enhanced Particle Therapy developed at ANSTO.

International fusion researchers, including  ANSTO’s Dr Richard Garrett, have recently returned from ITER in France where they attended a meeting of the coordinating committee of the International Tokomak Physics Activity (ITPA).

International fusion researchers recently returned from ITER in France where they attended a meeting of the coordinating committee of the International Tokomak Physics Activity.

Update on Nuclear medicine production at ANSTO.

Researchers and industry partners from UNSW Australia, the Australian Centre for Nanomedicine, Children’s Cancer Institute and Inventia Life Sciences Pty Ltd have been awarded the 2021 ANSTO Eureka Prize for Innovative Use of Technology for their method to rapidly-produce 3D cell structures

The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.

Beamtime guide on the SAX / WAXS beamline at the Australian Synchrotron.

ANSTO is engaged in international partnerships in the peaceful uses of nuclear science and technology throughout the world.

With the screening of the popular HBO series about Chernobyl, we asked our Nuclear Analysis team for their insights on key differences between the reactor in the TV series, a Generation II RBMK power reactor and ANSTO’s state of the art research reactor OPAL.

2025 marks the 150th anniversary of the signing of the Metre Convention—a milestone that underscores a century and a half of international collaboration in measurement science. T

Experiments at the Synchrotron enable researchers to produce a 3D structure of a molecular scaffold with role in cancer

Melbourne researchers have used the Australian Synchrotron to produce structure of molecule known to play a critical role in the development and spread of aggressive cancer.

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes for patients in earlier stages of this disease, a Peter Mac-led study has shown.